Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study.

Fauvet R, Demblocque E, Morice P, Querleu D, Daraï E.

Ann Surg Oncol. 2012 Mar;19(3):941-7. doi: 10.1245/s10434-011-2039-y. Epub 2011 Aug 31.

PMID:
21879267
3.

Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary.

Uzan C, Kane A, Rey A, Gouy S, Camatte S, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Morice P.

Oncologist. 2011;16(2):189-96. doi: 10.1634/theoncologist.2009-0139. Epub 2011 Jan 27.

4.

Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.

Laurent I, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P.

Ann Surg Oncol. 2008 Dec;15(12):3561-6. doi: 10.1245/s10434-008-0159-9. Epub 2008 Sep 27.

PMID:
18820973
5.

Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.

Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG.

Am J Surg Pathol. 2002 Sep;26(9):1129-41.

PMID:
12218569
6.

Micropapillary pattern in serous borderline ovarian tumors: does it matter?

Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Nam JH.

Gynecol Oncol. 2011 Dec;123(3):511-6. doi: 10.1016/j.ygyno.2011.08.008. Epub 2011 Sep 13.

PMID:
21917305
7.

Ovarian serous borderline tumors with invasive peritoneal implants.

Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C.

Cancer. 1998 Mar 15;82(6):1096-103.

PMID:
9506355
8.

A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component.

Slomovitz BM, Caputo TA, Gretz HF 3rd, Economos K, Tortoriello DV, Schlosshauer PW, Baergen RN, Isacson C, Soslow RA.

Am J Surg Pathol. 2002 May;26(5):592-600.

PMID:
11979089
9.
10.

Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.

Chang SJ, Ryu HS, Chang KH, Yoo SC, Yoon JH.

Acta Obstet Gynecol Scand. 2008;87(4):476-81. doi: 10.1080/00016340801995640.

PMID:
18382877
11.

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.

Silva EG, Gershenson DM, Malpica A, Deavers M.

Am J Surg Pathol. 2006 Nov;30(11):1367-71.

PMID:
17063075
12.

Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.

Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Daraï E.

Cancer. 2004 Mar 15;100(6):1145-51.

13.

Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.

Kane A, Uzan C, Rey A, Gouy S, Camatte S, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Morice P.

Oncologist. 2009 Jun;14(6):591-600. doi: 10.1634/theoncologist.2008-0263. Epub 2009 Jun 1.

14.

Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern.

Laurent I, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P.

BJOG. 2009 May;116(6):860-2. doi: 10.1111/j.1471-0528.2009.02118.x.

15.

Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.

Gilks CB, Alkushi A, Yue JJ, Lanvin D, Ehlen TG, Miller DM.

Int J Gynecol Pathol. 2003 Jan;22(1):29-36.

PMID:
12496695
16.

Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.

Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS.

Int J Gynecol Cancer. 2012 Jun;22(5):770-7. doi: 10.1097/IGC.0b013e31824b4076.

PMID:
22426410
17.

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR.

Am J Surg Pathol. 2005 Jun;29(6):707-23.

PMID:
15897738
18.

[Comparison of epidemiological factors between serous and mucinous borderline ovarian tumors: therapeutic implications].

Fauvet R, Demblocque É, Morice P, Querleu D, Gondry J, Daraï É.

Bull Cancer. 2012 May;99(5):551-6. doi: 10.1684/bdc.2012.1570. French.

PMID:
22510207
19.

Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.

Deffieux X, Morice P, Camatte S, Fourchotte V, Duvillard P, Castaigne D.

Gynecol Oncol. 2005 Apr;97(1):84-9.

PMID:
15790442
20.

Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.

Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG.

Gynecol Oncol. 2000 Jul;78(1):16-20.

PMID:
10873403
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk